Quick and effective method of bone marrow mesenchymal stem cell extraction

• Authors: Zivile Gudleviciene , Gabrielis Kundrotas , Regina Liudkeviciene , Jelena Rascon , Marcin Jurga
• Languages of publication: EN

Abstracts

EN

Background. Mesenchymal stem cells (MSCs) are currently exploited in numerous clinical trials to investigate their potential in immune regulation, hematopoesis or tissue regeneration. The most common source of MSCs for clinical use is human bone marrow. To generate sufficient numbers of cells relevant to clinical use in most cases the high volumes (20-50 ml) of bone marrow aspirates are taken. Methods. In this pilot study, 8 healthy bone marrow donors were included. Two different MSC extraction methods were evaluated: MSCs extraction from 60 ml of bone marrow using density gradient and MSCs extraction from 6 ml using red blood cell (RBC) lysis. Results. Our results showed that after RBC lysis the efficient amount of human MSCs can be isolated from 10 times less bone marrow volume (6 ml). Moreover, using small volume of bone marrow the adequate therapeutical dose of MSCs could be achieved during similar period of time (3-4 weeks). In conclusion, we have shown that MSCs isolation using RBC lysis is an effective and more advantageous method in comparison to standard MSCs isolation using density-gradient. Using RBC lysis from small volume of bone marrow the same amount of MSCs were obtained as usually using large volume and density-gradient.

Keywords

EN

Bone marrow; Cell therapy; Ficoll gradient; Mesenchymal stem cells; Red blood cell lysis

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2014
• Volume: 10
• Issue: 1

Dates

published

1 - 1 - 2015

received

21 - 3 - 2014

accepted

29 - 6 - 2014

online

8 - 10 - 2014

Contributors

author

Zivile Gudleviciene

• National Cancer Institute, Biobank, Santariskiu 1, 08660 Vilnius, Lithuania, tel. [phone], fax. [phone]

author

Gabrielis Kundrotas

• National Cancer Institute, Biobank Santariskiu 1, 08660 Vilnius, Lithuania Vilnius University, Faculty of Natural Sciences M.K. Ciurlionio 21/27, 03101 Vilnius

author

Regina Liudkeviciene

• National Cancer Institute, Biobank Santariskiu 1, 08660 Vilnius, Lithuania

author

Jelena Rascon

• Children‘s Hospital, Affiliate of Vilnius Unversity Hospital Santariskiu Klinikos, Children Heamatology and Transplantation Center Santariskiu 7, 08406, Vilnius, Lithuania

author

Marcin Jurga

• Cryo-Save Labs NV, Attn. The Cell Factory (R&D department) Galileilaan 19, B-2845 Niel, Belgium

References

• [1] Beyer N.N., Meirelles S.L., Mesenchymal Stem Cells: Isolation, In Vitro Expansion and Characterization, In: Wobus A.M. and Boheler K.R. (Eds), Stem cells, vol. 174, Handbook of experimental pharmacology, New York: Springer-Verland Berlin Heidelberg, 2006, 249-282
• [2] Bieback K., Schallmoser K., Kluter H., Strunk D., Clinical Protocols for the Isolation and Expansion of Mesenchymal Stromal Cells, Transfus. Med. Hemother., 2008, 35(4), 286-294[WoS]
• [3] Jung S., Panchalingam K.M., Rosenberg L., Behie L.A., Ex vivo expansion of human mesenchymal stem cells in defined serum-free media, Stem Cells Int., 2012, 2012:123030, DOI: 10.1155/2012/123030[WoS]
• [4] Thirumala S., Goebel W.S., Woods E.J., Clinical grade adult stem cell banking, Organogenesis, 2009, 5(3), 143-154[WoS][Crossref]
• [5] Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., at al., Mesenchymal stem cells for treatment of steroidresistant, severe, acute graft-versus-host disease: a phase II study, Lancet, 2008, 371(9624), 1579-1586
• [6] Venkataramana N.K., Kumar S.K., Balaraju S., Radhakrishnan R.C., Bansal A., Dixit A., et al., Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson’s disease, Transl. Res., 2010, 155(2), 62-70[Crossref][WoS]
• [7] Lee H., Park J.B., Lee S., Baek S., Kim H., Kim S.J., Intra-osseous injection of donor mesenchymal stem cell (MSC) into the bone marrow in living donor kidney transplantation; a pilot study, J. Transl. Med., 2013, 11-96[WoS]
• [8] Hass R., Kasper C., Bohm S., Jacobs R., Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC, Cell Commun. Signal., 2011, 9-12[WoS]
• [9] Cooper K., Viswanathan C., Establishment of a mesenchymal stem cell bank, Stem Cells Int., 2011, 2011, 905621[WoS]
• [10] Horn P., Bork S., Diehlmann A., Walenda T., Eckstein V., Ho A.D., et al., Isolation of human mesenchymal stromal cells is more efficient by red blood cell lysis, Cytotherapy, 2008, 10(7), 676-685[Crossref][WoS]
• [11] Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al., Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement, Cytotherapy, 2006, 8(4), 315-317[Crossref]
• [12] Buhring H.J., Treml S., Cerabona F., de Zwart P., Kanz L., Sobiesiak M., Phenotypic characterization of distinct human bone marrow-derived MSC subsets, Ann. N.Y. Acad. Sci., 2009, 1176, 124-134[Crossref]
• [13] Ringden O., Le Blanc K., Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages, Best Pract. Res. Clin. Haematol., 2011, 24(1), 65-72[WoS][Crossref]
• [14] Fennema E.M., Renard A.J., Leusink A., van Blitterswijk C.A., de Boer J., The effect of bone marrow aspiration strategy on the yield and quality of human mesenchymal stem cells, Acta Orthop., 2009, 80(5), 618-621[WoS][Crossref]
• [15] Le Blanc K., Rasmusson I., Sundberg B., Gotherstrom C., Hassan M., Uzunel M., et al., Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells, Lancet, 2004, 363(9419), 1439-1441
• [16] Sensebe L., Bourin P., Tarte K., Good manufacturing practices production of mesenchymal stem/stromal cells, Hum. Gene Ther., 2011, 22(1), 19-26[Crossref][WoS]
• [17] Horn P., Bokermann G., Cholewa D., Bork S., Walenda T., Koch C., at al., Impact of individual platelet lysates on isolation and growth of human mesenchymal stromal cells, Cytotherapy, 2010, 12(7), 888-898[WoS][Crossref]
• [18] Fekete N., Gadelorge M., Furst D., Maurer C., Dausend J., Fleury- Cappellesso S., et al., Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components, Cytotherapy, 2012, 14(5), 540-554[WoS]
• [19] Fekete N., Rojewski M.T., Furst D., Kreja L., Ignatius A., Dausend J., et al., GMP-compliant isolation and large-scale expansion of bone marrow-derived MSC, PLoS One, 2012, 7(8), e43255
• [20] Schrezenmeier H., Seifried E., Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred?, Vox. Sang., 2010, 99, 1-15[WoS]
• [21] Otsuru S., Hofmann T.J., Olson T.S., Dominici M., Horwitz E.M., Improved isolation and expansion of bone marrow mesenchymal stromal cells using a novel marrow filter device, Cytotherapy, 2013, 15(2), 146-153[WoS][Crossref]

Identifiers

DOI

10.1515/med-2015-0008